[Zhou Jun] the growth of these anti-tumor drugs in the world is strong, contributing more than 10 billion yuan; the first "4 + 7" linked province is coming; 3 pharmaceutical companies have made new progress in snatching Nash blue ocean market
-
Last Update: 2019-02-18
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
This week's highlights: 1 Guangzhou GPO set hands on 15 major varieties and set the national lowest price 2 The first "4 + 7" linkage province is coming, and the winning drugs can get 60% of the market 3 The scope continues to expand, and 3 provincial trusteeship pharmacies are stopped! 4 In 2018, these anti-tumor drugs contributed more than 10 billion yuan, driving the growth of giant drug companies 5 The Nash market was more than 10 billion yuan Geli, guangshengtang and xianweida biology were laying out policies Guangzhou GPO started to work on 15 major varieties In December 2018, Guangzhou announced that the top 20 drugs purchased in the previous year would be included in the first batch of medical insurance group negotiations Subsequently, sodium chloride took the lead in completing the negotiation on January 20; four varieties of clopidogrel, entecavir, atorvastatin and amlodipine were "4 + 7" varieties, which did not need to be negotiated again On February 13, Guangzhou GPO procurement platform issued a notice to negotiate the remaining 15 drugs such as recombinant human granulocyte stimulating factor According to the notice, the relevant varieties must submit the national lowest price within the specified time before participating in the negotiation The negotiation first enters into the man-machine negotiation link, which is carried out with reference to the lowest price in China If the purchase amount is high or the price reduction is insufficient, it will enter the expert negotiation phase According to the database of drug intelligence assistance and key monitoring drugs, among the 15 drugs, including olacetam, paclitaxel, sodium creatine phosphate, budesonide, Kangai, alprostadil, etc., are the auxiliary drugs under multiple key monitoring The first "4 + 7" linkage province is coming, and 60% of the market can be obtained for the winning drugs According to media reports, during the Spring Festival, Fujian Province is soliciting opinions on the "implementation plan (discussion draft) for Fujian Province to fully implement and follow up the pilot work of centralized drug purchase and use organized by the state" According to the discussion draft of the implementation plan, the 4 + 7 volume procurement of the selected products can enjoy 60% of the basic procurement volume of Fujian Province directly; Xiamen may be implemented on March 1, and the whole province may be implemented on April 1 Previously, Gansu and Shaanxi said that enterprises that voluntarily use 4 + 7 negotiation price to connect to the Internet in our province would be listed in the price limit network directory first, and price linkage was not clear Shandong, Sichuan and other provinces also said they would carry out provincial and municipal linkage and price tracking, but they did not take action If the document can be issued successfully this time, Fujian will become the first province to link with each other and promote 4 + 7 volume procurement in the whole province The scope continues to expand, and 3 provincial trusteeship pharmacies have been stopped! Since February, Hebei, Jiangsu and Guangdong have issued documents calling for the suspension of the contracting, leasing and Trusteeship of public hospital pharmacies Jiangsu Province, in the notice on comprehensively stopping the trusteeship of pharmacies of public medical institutions, requires all public medical institutions in Jiangsu Province not to contract or rent pharmacies, not to trusteeship pharmacies to enterprises or carry out similar business cooperation with enterprises, and those already trusteeship or disguised trusteeship shall be immediately stopped In the opinions on speeding up the development of pharmaceutical service with high quality, Guangdong Province proposed to adhere to the public welfare nature of public hospital pharmacies Public hospitals should not contract, rent or trust pharmacies to profit-making enterprises Hebei also announced that it should adhere to the public welfare nature of public hospital pharmacies and prohibit public hospitals from contracting, renting or trusting pharmacies to profit-making enterprises In addition to the above three provinces, since November 26, 2018, the opinions on accelerating the high-quality development of pharmaceutical services jointly issued by the national health and Health Commission and the State Administration of traditional Chinese medicine clearly pointed out that "public hospitals shall not contract or rent pharmacies, and shall not trust pharmacies to profit-making enterprises", Beijing, Shandong, Guizhou, Ningxia, Hainan, Gansu, Guangdong, Henan, Xinjiang, Shanxi And other provinces have also introduced the latest policies to put an end to the contracting, leasing and Trusteeship of public hospital pharmacies Market hotspots in 2018, these anti-tumor drugs contributed more than 10 billion yuan Under the adverse pressure of patent cliff, generic impact and other adverse pressures, AstraZeneca has experienced several years of performance decline, and finally ushered in a turning point in 2018 On February 14, AstraZeneca announced its 2018 financial report, with product sales of US $21.049 billion, up 4% year on year The most eye-catching growth is in the tumor business, including tagrisso (ositini) revenue of US $1.86 billion, an increase of 95%; lynparza (olapari) revenue of US $647 million, an increase of 118%; imfinzi (duvalmonab) global revenue of US $633 million, up from US $19 million in 2017 From these three drugs, we can see the driving ability of tumor business In addition to AstraZeneca, pharmaceutical giants such as Merck, Pfizer and Johnson & Johnson have made a lot of contributions to the growth of their annual revenue More than 50% of Bristol Myers Squibb's revenue in 2018 was contributed by two drugs, one of which was opdivo (nafulizumab) In 2018, the sales volume was 6.735 billion US dollars, an increase of 36%, which was an increase compared with 31% in 2017 Keysruda (pablizumab) of mosadon reached an astonishing $71.71 in 2018, and the 88% growth rate of the whole year eclipsed opdivo As a small molecule drug, Pfizer's growth momentum is comparable to that of pd-12018, which went on the market in the same period, achieving 32% growth in 2018, bringing Pfizer $4.118 billion in revenue and becoming the main driving force of Pfizer's growth Imbruvica's commercial rights in the U.S market are owned by abbvie In 2018, the sales volume was $3.59 billion, an increase of 39.5%, which is comparable to the 38.1% increase of Johnson & Johnson's international market It has become another strong growth engine in addition to ibuprofen and hepatitis C drugs The sales revenue of Johnson darzalex in 2018 was US $2.025 billion, an increase of 63% It is well complementary to the growth of psoriasis drugs and pulmonary hypertension drugs Tafinlar + mekinist, a melanoma and lung cancer drug that Novartis replaced with GSK assets, had sales of 1.155 billion yuan, an increase of 32% In addition, new drugs with strong growth include kisquali, a CDK4 / 6 inhibitor, and lutathera, a radiation oncology drug purchased from AAA, with sales of US $235 million and US $167 million, respectively Over 10 billion Nash markets have been snapped up Geli, guangshengtang and xianweida have made new progress this week The good news of Nash innovative drug market is continuous: gst-hg151, the original drug with global intellectual property rights of guangshengtang, and the clinical application of global innovative drug reversible by non-alcoholic fatty liver disease and liver fibrosis has been accepted The company said that in the future, it is expected to become the world's heavyweight first-line innovative drug by superimposing the country's priority policy for major new drugs during the 13th five year plan Through cooperation, Geli obtained the exclusive rights and interests in the development, manufacturing and commercialization of tvb-2640, the global first drug of 3-vbiosciences and related compounds in Greater China At the same time, 3-vbiosciences also completed the e-round financing of 18 million US dollars led by Geli, which was used for the continuous development of tvb-2640, including the Nash clinical phase II Research in the United States and China Focusing on the research and development of Nash new drugs, we first completed the round a financing of nearly 200 million RMB for dabio In 2019, xianweida will have 2 class I new drugs with international intellectual property rights submitted to ind Behind the pursuit of enterprises and the continuous influx of capital, there is a huge blue ocean market According to the announcement of guangshengtang, no drugs have been approved for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic fatty hepatitis (NASH) in the world According to relevant data and forecasts, once the relevant patent drugs for NASH indications are approved for marketing, the drug market will exceed 15 billion US dollars by 2025 The production and sale of furazolidone containing compound preparations were suspended 12 enterprises were affected On December 15, the State Food and Drug Administration announced that there were serious adverse reactions of furazolidone containing compound preparations, and the risk of use was greater than the benefit in China It was decided to stop the production, sale and use of furazolidone containing compound preparations in China from now on, and cancel the drug approval certificate The manufacturer shall be responsible for the recall of the products that have been put on the market, and after the recall, the local drug regulatory department shall supervise the destruction The event will involve 12 enterprises in the production of compound xuedanfurazolidone capsules, furmatrine Berberine Tablets, 2D furazolidone tablets and guhaisheng tablets, including China Resources Sanjiu (Ya'an) Pharmaceutical Co., Ltd., Guizhou magic Pharmaceutical Co., Ltd and Gansu LAN Pharmaceutical Co., Ltd Taurine manufacturers accused of infringement in the US On February 11, Yong'an pharmaceutical announced that the information on the official website of the Ministry of Commerce of the people's Republic of China showed that vitaworks IP company, vitaworks company and other applicants filed an application with the International Trade Commission (ITC) of the United States in accordance with Section 337 of the tariff act of 1930, accusing the taurine (2-aminoethanesulfonic acid) products exported, imported or sold in the United States and their production process of infringing upon the United States In violation of its patent right, ITC is requested to launch 337 investigation and issue limited exclusion and prohibition orders In addition to Yong'an pharmaceutical, Hubei Yuanda life science and Technology Co., Ltd., Jiangsu Jiangyin Huachang Food Additive Co., Ltd and related customers in the industry are also applying Content source: statement of State Food and drug administration, health and information administration, public announcement of listed enterprises, medical cloud studio, etc.: this point of view only represents the author, not the position of pharmaceutical intelligence network, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.